Search Results

therapy to prevent heart failure progression GPCR Binders, Drugs, and more Advances in GPCR-targeted drug development Announces EUR 60M Series B Financing to Advance a Pipeline of Novel GPCR-Modulating Therapies into Clinical Development

chemical biology: a mini-review YAP/TAZ: Molecular pathway and disease therapy Primary cilia in skeletal development Business Update for Second Quarter and First Half of 2023 Novo Nordisk to acquire Inversago Pharma to develop

Progressive Technologies and Approaches Revealing Novel GPCR Biology and Drug Development Potential. Computational drug design postdoc at the Department of Drug Design and Pharmacology Software / database development PhD student at Department of Drug Design and Pharmacology Software / database development postdoc at

Exclusive Deal for Scientists in Developing Nations If you reside and work in a developing country, complete

whole-genome SNP-based analysis Industry News Boehringer Ingelheim and Sosei Heptares join forces to develop Deciphering the role of GPCRs in obesity pathology for drug development GPCR Events, Meetings, and Webinars

CCR9) antagonist and previous phase III clinical candidate for the treatment of Crohn's disease, we developed To chemically induce CCR9 degradation, we then developed the first PROTAC targeting the IABS of GPCRs

concept of biased agonism has been effectively leveraged in drug discovery, as demonstrated by the development By selectively targeting specific signaling pathways, it is possible to develop drugs with improved efficacy

, a clinical-stage pharmaceutical company pioneering allosteric modulation-based drug discovery and development completion of this Phase 1 safety program will enable centers in Japan to be included in a potential global development

Recently, several high-throughput screening (HTS) assays for ERK activation have been developed, each In summary, targeting GPCR-activated ERK pathways represents a promising strategy for developing new

Although several B2R agonists and antagonists have been developed, icatibant is the only B2R antagonist

, a clinical-stage pharmaceutical company pioneering allosteric modulation-based drug discovery and development

Essential to the further development of such applications, however, is a clearer understanding of how

ligands acting on neurotransmitter receptors have shown great potential for inhibiting GBM growth and development

biochemical and structural studies of class IB phosphoinositide 3-kinases There is considerable interest in developing work reveals insight into PI3Kγ regulation and identifies sites that may be exploited for therapeutic development

dysregulation of TLR4 contributes to numerous diseases, which highlights the importance of biased modulator development The discovery of biased modulators of TLR4 would provide insight for the future development of biased

"We are an experienced, innovative, global team on a bold mission to improve health by creating and developing

These complex properties have driven the need for development of specialized tools that can sense neuropeptide

As new technologies are developed and applied to studying GPCR structure and their downstream effectors

Research Collaboration Neurocrine Biosciences and Voyager Therapeutics Enter Strategic Collaboration for Development Progressive Technologies and Approaches Revealing Novel GPCR Biology and Drug Development Potential.

Sosei Heptares, which have struck a research agreement to discover new GPCR targets that’ll fuel the development

approved drugs over previous decades—but the two-year-old biotech believes the area is still ripe for development

In a constant effort to develop drugs with less side effects, and tools to explore the ORs nature and

GPCR Binders, Drugs, and more Persistent challenges in the development of an mGlu7 PAM in vivo tool compound Progressive Technologies and Approaches Revealing Novel GPCR Biology and Drug Development Potential.

recognizes the combination of Steyaert’s fundamental research and his ability to apply the research to the development

biopharmaceutical company and world-leader in GPCR1-focused structure-based drug design (SBDD) and development

For GPCR assay developers, HCS supports:  Quantitative visualization of receptor internalization and fluorescent ligand technologies without needing internal imaging infrastructure or specialized assay development

(Nasdaq: TRVN), a biopharmaceutical company focused on the development and commercialization of novel

Encouraging Phase 1 results and supportive preclinical package assist in the launch of Phase 2 clinical development

Progressive Technologies and Approaches Revealing Novel GPCR Biology and Drug Development Potential. Antibody Engineering Scientist—Immuno-Oncology Convergent Research - Senior Scientist, Cell-Based Assay Development

Drugs, and more Engineered Human Antibody with Improved Endothelin Receptor Type A Binding Affinity, Developability BioSpace Sosei Heptares Notes its Partner Tempero Bio has Received FDA Clearance to Advance Clinical Development Progressive Technologies and Approaches Revealing Novel GPCR Biology and Drug Development Potential.